A Kerasnoudis1, K Pitarokoili2, V Behrendt3, R Gold4, M-S Yoon5. 1. Department of Neurology, St. Josef Hospital, Ruhr University of Bochum, Germany. Electronic address: antonis.kerasnoudis@gmail.com. 2. Department of Neurology, St. Josef Hospital, Ruhr University of Bochum, Germany. Electronic address: kalliapit@yahoo.gr. 3. Department of Neurology, St. Josef Hospital, Ruhr University of Bochum, Germany. Electronic address: volker.behrendt@gmx.net. 4. Department of Neurology, St. Josef Hospital, Ruhr University of Bochum, Germany. Electronic address: Ralf.Gold@ruhr-uni-bochum.de. 5. Department of Neurology, St. Josef Hospital, Ruhr University of Bochum, Germany. Electronic address: min-suk.yoon@uni-due.de.
Abstract
OBJECTIVE: Aim of this study was to develop and evaluate the applicability of an ultrasound score (Bochum ultrasound score - BUS) in distinguishing chronic (CIDP) from acute inflammatory demyelinating polyneuropathy (AIDP). METHODS: Step 1: For the development of BUS 75 healthy-controls, 20 CIDP, 20 AIDP patients underwent US 4.55 ± 3.5 and 3.4 ± 2.91 years, respectively after onset. After comparing the distribution pattern and frequency of pathological US changes between the two study groups, we developed BUS, summarizing the cross sectional area (CSA) of: (1) the ulnar nerve in Guyons' canal, (2) the ulnar nerve in upper-arm, (3) the radial nerve in spiral groove, (4) the sural nerve between the gastrocnemius muscle. Step 2: The BUS underwent blinded evaluation in further 10 CIDP, 21 AIDP patients 3.8 ± 2.7 and 2.3 ± 1.5 years, respectively after onset. Step 3: The BUS underwent blinded, prospective evaluation in 8 patients with acute/subacute polyradiculoneuropathy (5 CIDP, 3 AIDP) 2.6 ± 1.8 weeks after onset. RESULTS: The BUS showed a sensitivity of 90% and specificity of 90.4% (positive predictive value, PPV=81.8%; negative predictive value, NPV=95%) in distinguishing CIDP from AIDP, when they showed no differences in disease duration (p=0.0551).In addition, the BUS distinguished subacute-CIDP from AIDP with a sensitivity of 80%, specificity of 100% (PPV=100%, NPV=75%). CONCLUSION: The BUS seems to allow a reliable distinction of CIDP from AIDP. SIGNIFICANCE: The BUS may be helpful in distinguishing subacute-CIDP from AIDP.
OBJECTIVE: Aim of this study was to develop and evaluate the applicability of an ultrasound score (Bochum ultrasound score - BUS) in distinguishing chronic (CIDP) from acute inflammatory demyelinating polyneuropathy (AIDP). METHODS: Step 1: For the development of BUS 75 healthy-controls, 20 CIDP, 20 AIDP patients underwent US 4.55 ± 3.5 and 3.4 ± 2.91 years, respectively after onset. After comparing the distribution pattern and frequency of pathological US changes between the two study groups, we developed BUS, summarizing the cross sectional area (CSA) of: (1) the ulnar nerve in Guyons' canal, (2) the ulnar nerve in upper-arm, (3) the radial nerve in spiral groove, (4) the sural nerve between the gastrocnemius muscle. Step 2: The BUS underwent blinded evaluation in further 10 CIDP, 21 AIDP patients 3.8 ± 2.7 and 2.3 ± 1.5 years, respectively after onset. Step 3: The BUS underwent blinded, prospective evaluation in 8 patients with acute/subacute polyradiculoneuropathy (5 CIDP, 3 AIDP) 2.6 ± 1.8 weeks after onset. RESULTS: The BUS showed a sensitivity of 90% and specificity of 90.4% (positive predictive value, PPV=81.8%; negative predictive value, NPV=95%) in distinguishing CIDP from AIDP, when they showed no differences in disease duration (p=0.0551).In addition, the BUS distinguished subacute-CIDP from AIDP with a sensitivity of 80%, specificity of 100% (PPV=100%, NPV=75%). CONCLUSION: The BUS seems to allow a reliable distinction of CIDP from AIDP. SIGNIFICANCE: The BUS may be helpful in distinguishing subacute-CIDP from AIDP.
Authors: Kai F Loewenbrück; Markus Dittrich; Josef Böhm; Jürgen Klingelhöfer; Petra Baum; Jochen Schäfer; Rainer Koch; Alexander Storch Journal: J Neurol Date: 2016-08-08 Impact factor: 4.849
Authors: Vera Bril; Christopher M Blanchette; Joshua M Noone; M Chris Runken; Deborah Gelinas; James W Russell Journal: J Diabetes Complications Date: 2016-05-10 Impact factor: 2.852
Authors: Maria Rasenack; Bernhard F Décard; Sabine Schädelin; Alexander Grimm; Dirk Fischer; Patricia Hafner Journal: BMJ Open Date: 2016-12-09 Impact factor: 2.692